{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:10:41Z","timestamp":1773227441533,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015258","name":"Zhejiang Provincial People's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.numecd.2025.104359","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:18:29Z","timestamp":1757769509000},"page":"104359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of low-dose febuxostat on arterial stiffness in elderly patients with asymptomatic hyperuricemia: A prospective, longitudinal cohort study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-0017","authenticated-orcid":false,"given":"Xiuxiu","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gongmin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijia","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3644-9518","authenticated-orcid":false,"given":"Qihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.numecd.2025.104359_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11926-022-01069-3","article-title":"Update on uric acid and the kidney","volume":"24","author":"Ramos","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.numecd.2025.104359_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2478\/jtim-2022-0031","article-title":"Prevalence and risk factors of hyperuricemia and gout: a cross-Sectional survey from 31 provinces in mainland China","volume":"10","author":"Song","year":"2022","journal-title":"J Transl Int Med"},{"key":"10.1016\/j.numecd.2025.104359_bib3","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1038\/s41598-018-22570-9","article-title":"Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China","volume":"8","author":"Song","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2025.104359_bib4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.40472","article-title":"U-Shaped association between serum uric acid level and risk of mortality: a cohort study","volume":"70","author":"Cho","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.numecd.2025.104359_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.582680","article-title":"Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective","volume":"11","author":"Yu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.numecd.2025.104359_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040942","article-title":"The optimal range of serum uric acid for cardiometabolic diseases: a 5-Year Japanese cohort study","volume":"9","author":"Kuwabara","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2025.104359_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","article-title":"Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases five-year Japanese cohort study","volume":"69","author":"Kuwabara","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2025.104359_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ndt\/gfad201","article-title":"Serum uric acid levels and health outcomes in CKD: a prospective cohort study","volume":"39","author":"Wu","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.numecd.2025.104359_bib9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/CIRCRESAHA.121.318061","article-title":"Arterial stiffness and cardiovascular risk in hypertension","volume":"128","author":"Boutouyrie","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2025.104359_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.11.083","article-title":"Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications","volume":"77","author":"Palombo","year":"2016","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.numecd.2025.104359_bib11","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/HYPERTENSIONAHA.123.21314","article-title":"Reimagining the value of brachial-ankle pulse wave velocity as a biomarker of cardiovascular disease Risk-A call to action on behalf of VascAgeNet","volume":"80","author":"Stone","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2025.104359_bib12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/HYPERTENSIONAHA.118.11390","article-title":"Involvement of arterial stiffness and inflammation in hyperuricemia-related development of hypertension","volume":"72","author":"Tomiyama","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2025.104359_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijcard.2018.03.077","article-title":"LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: data from the brisighella heart study cohort","volume":"261","author":"Cicero","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2025.104359_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/HJH.0b013e328365b916","article-title":"Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the brisighella heart study","volume":"32","author":"Cicero","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2025.104359_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"American College of Rheumatology Guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.numecd.2025.104359_bib16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1053\/j.ajkd.2024.04.017","article-title":"Efficacy and safety of allopurinol and febuxostat in patients with gout and CKD: subgroup analysis of the STOP gout trial","volume":"84","author":"Helget","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.numecd.2025.104359_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00296-013-2857-2","article-title":"As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout","volume":"34","author":"Tausche","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.numecd.2025.104359_bib18","article-title":"Inhibition of xanthine oxidase protects against diabetic kidney disease through the amelioration of oxidative stress via VEGF\/VEGFR axis and NOX-FoxO3a-eNOS signaling pathway","volume":"24","author":"Yang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104359_bib19","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cpt.3217","article-title":"Impacts of febuxostat on cerebral and cardiovascular events in elderly patients with hyperuricemia: analysis of a randomized controlled trial","volume":"115","author":"Sugawara","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.numecd.2025.104359_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003095","article-title":"Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial","volume":"17","author":"Tanaka","year":"2020","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.numecd.2025.104359_bib21","first-page":"13","article-title":"Guideline for the diagnosis and treatment of hyperuricemia and gout in China(2019)","volume":"36","year":"2020","journal-title":"Chinese J Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.numecd.2025.104359_bib22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1159\/000540701","article-title":"Effects of febuxostat therapy on circulating adipokine profiles in patients with overweight or obesity and asymptomatic hyperuricemia: a randomized controlled study","volume":"17","author":"Dong","year":"2024","journal-title":"Obes Facts"},{"issue":"6","key":"10.1016\/j.numecd.2025.104359_bib23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.numecd.2025.104359_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152073","article-title":"Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: a meta-analysis of observational studies","volume":"56","author":"Jeong","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.numecd.2025.104359_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5603\/cj.98254","article-title":"Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update","volume":"31","author":"Borghi","year":"2024","journal-title":"Cardiol J"},{"issue":"10075","key":"10.1016\/j.numecd.2025.104359_bib26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104359_bib27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/clinchem\/hvab282","article-title":"Clinical impact of the refit CKD-EPI 2021 creatinine-based eGFR equation","volume":"68","author":"Meeusen","year":"2022","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.numecd.2025.104359_bib28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"American college of rheumatology guideline for the management of gout","volume":"72","author":"Fitzgerald","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.numecd.2025.104359_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039738","article-title":"Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS One"},{"issue":"3\u20134","key":"10.1016\/j.numecd.2025.104359_bib30","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1159\/000345509","article-title":"Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations","volume":"121","author":"Sanchez-Lozada","year":"2012","journal-title":"Nephron Exp Nephrol"},{"issue":"2","key":"10.1016\/j.numecd.2025.104359_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/HJH.0b013e3282f240bf","article-title":"Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system","volume":"26","author":"Corry","year":"2008","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.numecd.2025.104359_bib32","doi-asserted-by":"crossref","first-page":"p69","DOI":"10.1159\/000127837","article-title":"Effect of febuxostat on the progression of renal disease in 5\/6 nephrectomy rats with and without hyperuricemia","volume":"108","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephron Physiol"},{"issue":"4","key":"10.1016\/j.numecd.2025.104359_bib33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10157-012-0609-3","article-title":"Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy","volume":"16","author":"Omori","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.numecd.2025.104359_bib34","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2337\/db12-1814","article-title":"Sugar, uric acid, and the etiology of diabetes and obesity","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104359_bib35","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1096\/fj.14-267393","article-title":"IL-1\u03b2 production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages","volume":"29","author":"Gicquel","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.numecd.2025.104359_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063188","article-title":"Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment","volume":"23","author":"Gherghina","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104359_bib37","first-page":"1195","article-title":"Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study","volume":"38","author":"Pineda","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.numecd.2025.104359_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/15257770.2015.1124999","article-title":"Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout","volume":"35","author":"Puig","year":"2016","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.numecd.2025.104359_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X15599734","article-title":"Hyperuricaemia with deposition: latest evidence and therapeutic approach","volume":"7","author":"Perez-Ruiz","year":"2015","journal-title":"Ther Adv Musculoskel"},{"key":"10.1016\/j.numecd.2025.104359_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063188","article-title":"Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment","volume":"23","author":"Gherghina","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104359_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00424-021-02606-2","article-title":"Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection","volume":"474","author":"Bahadoran","year":"2022","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.numecd.2025.104359_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032960","article-title":"Role of uric acid in vascular remodeling: Cytoskeleton changes and migration in VSMCs","volume":"24","author":"Russo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104359_bib43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/HJH.0b013e328013e7c4","article-title":"Xanthine oxidase-derived extracellular superoxide anions stimulate activator protein 1 activity and hypertrophy in human vascular smooth muscle via c-Jun N-terminal kinase and p38 mitogen-activated protein kinases","volume":"25","author":"Matesanz","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2025.104359_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/ajh\/hpy157","article-title":"Xanthine oxidase inhibition by febuxostat in macrophages suppresses angiotensin II-Induced aortic fibrosis","volume":"32","author":"Kondo","year":"2019","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.numecd.2025.104359_bib45","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41440-022-00857-9","article-title":"Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study","volume":"45","author":"Shiina","year":"2022","journal-title":"Hypertens Res"},{"key":"10.1016\/j.numecd.2025.104359_bib46","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1253\/circj.CJ-13-0082","article-title":"Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH trial)","volume":"77","author":"Sezai","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.numecd.2025.104359_bib47","article-title":"Effect of the xanthine oxidase inhibitor febuxostat on the cardio-ankle vascular index in asymptomatic patients with hyperuricemia and liver dysfunction: a sub-analysis of the PRIZE study","author":"Kawachi","year":"2024","journal-title":"J Atherosclerosis Thromb"},{"issue":"1","key":"10.1016\/j.numecd.2025.104359_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00296-013-2857-2","article-title":"As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout","volume":"34","author":"Tausche","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.numecd.2025.104359_bib49","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jch.14153","article-title":"Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia","volume":"23","author":"Kario","year":"2021","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.numecd.2025.104359_bib50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/ehjcvp\/pvaa144","article-title":"Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study","volume":"8","author":"Desideri","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.numecd.2025.104359_bib51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-Yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.numecd.2025.104359_bib52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/clc.23643","article-title":"Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis","volume":"44","author":"Gao","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.numecd.2025.104359_bib53","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cpt.3217","article-title":"Impacts of febuxostat on cerebral and cardiovascular events in elderly patients with hyperuricemia: post hoc analysis of a randomized controlled trial","volume":"115","author":"Sugawara","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.numecd.2025.104359_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186096","article-title":"Triggers of acute attacks of gout, does age of gout onset matter? A primary care based cross-sectional study","volume":"12","author":"Abhishek","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2025.104359_bib55","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325005137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325005137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:18:36Z","timestamp":1773152316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325005137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0939475325005137"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104359","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of low-dose febuxostat on arterial stiffness in elderly patients with asymptomatic hyperuricemia: A prospective, longitudinal cohort study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104359"}}